Vor tinerețe fără bătrânețe. Miliardarii din Silicon Valley sunt obsedați să își „programeze” corpurile ca să trăiască cât mai mult

Silicon Valley billionaires are investing in cellular reprogramming to extend life. Life Biosciences is conducting the first human trial for this technology, focusing on glaucoma treatment. Initial results show promise, with some patients experiencing improved vision. If successful, this approach could address various age-related diseases. Other biotech startups are also preparing to explore similar therapies.